Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group, Phase III Clinical Trial To Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration

NCT04857177 is registered in ClinicalTrials.gov with Chong Kun Dang Pharmaceutical as lead sponsor.

NCT NCT04857177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04857177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group, Phase III Clinical Trial To Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration
Lead sponsor
Chong Kun Dang Pharmaceutical
Phase
Phase 3
Overall status
Completed
Start date
October 19, 2018
Completion date
March 17, 2021
Enrollment
312 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular(wet) age related macular degeneration